Plant Sterols and Plant Stanols in the Management of Dyslipidaemia and Prevention of Cardiovascular Disease

The grocery store is full of margarines and yogurt drinks promising to lower cholesterol. This European Atherosclerosis Society consensus is a sober attempt to separate what those products can actually do from what their marketing implies.

The panel’s verdict is measured. Plant sterols and stanols — compounds that block cholesterol absorption in the gut — reliably lower LDL cholesterol by roughly 7 to 12 percent at a daily dose of about 2 grams. That effect is real, reproducible, and additive to a statin. So as one component of a cholesterol-lowering lifestyle, or as a modest adjunct in people who cannot reach goal, they have a defensible place.

The crucial limitation, which the document is careful to state, is the missing endpoint. There is good evidence that these compounds lower the LDL number, but no randomized trial showing they prevent heart attacks or deaths. For a marker that is itself a stand-in for events, that gap matters — and there have been lingering theoretical concerns about sterols accumulating in the bloodstream.

We rate the evidence moderate. It is a rigorous, balanced appraisal of a popular intervention, honest about the difference between lowering a lab value and changing an outcome. For a reader trying to spend effort where it counts, the practical message is that plant sterols are a reasonable accessory to cardiovascular prevention — not a substitute for the therapies that have actually been shown to extend life.